Abstracts tagged "Systemic sclerosis"

Abstract Number: 2498 • ACR Convergence 2025
Effect of autologous myeloablative hematopoietic stem cell transplantation on skin and peripheral blood mononuclear cells in systemic sclerosis patients with interstitial lung disease
Poulami Dey¹, Rachael Bogle², Qinmengge Li³, Olesya Plazyo⁴, Rosemary Gedert⁴, Carleigh Zahn⁴, Pei-Suen Tsou⁴, John Varga⁴, Lam Tsoi⁴, Johann Gudjonsson⁴ and Dinesh Khanna⁴, ¹Michigan Medicine, Ann Arbor, MI, ²University of Michigan, Holland, OH, ³University of Michigan, Ypsilanti, MI, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is characterized by skin fibrosis, dysregulated immune response, and vascular system dysfunction. Interstitial lung disease (ILD) is one of the leading…
Abstract Number: 2473 • ACR Convergence 2025
Nailfold Capillaroscopy Improves Cardiovascular Risk Stratification in Systemic Sclerosis: An Adjustment to the SCORE2 Algorithm
Carlos Valera Ribera¹, Javier Narváez², Joaquin Lacasa Molina³, Adrián Mayo-Juanatey⁴, Paula Mencio⁵, Patricia Leon Torralba⁵, Pablo Andujar Brazal⁵, Ignacio Vázquez Gómez⁶ and JUAN JOSE ALEGRE SANCHO⁷, ¹Hospital Universitario Doctor Peset, València, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitario Doctor Peset, Valencia, Spain, ⁴Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, ⁵Hospital Universitario Doctor Peset, València, Comunidad Valenciana, Spain, ⁶H.U. Doctor Peset, Valencia, ⁷Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain
Background/Purpose: Systemic sclerosis (SSc) is associated with both micro- and macrovascular damage, increasing cardiovascular (CV) risk. The SCORE2 algorithm estimates CV event risk in the…
Abstract Number: 1863 • ACR Convergence 2025
Bag3 in systemic sclerosis: possible therapeutic target and biomarker for pulmonary fibrosis
Claudia Iannone¹, Margot De Marco², Antonina Minniti³, Giuseppe Armentaro⁴, Antonia Falco², Angela D'Ardia², paola Manzo², Liberato Marzullo⁵, Anna Basile², Alessandra Rosati², Maria Caterina Turco², Roberto Caporali⁶ and Nicoletta Del Papa⁷, ¹University of Milan, Gaetano Pini CTO, Milano, Milan, Italy, ²Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, Italy, Baronissi, Campania, Italy, ³ASST Gaetano Pini, milano, Milan, Italy, ⁴ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ⁵Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, Italy, Baronissi, Italy, ⁶University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ⁷ASST Pini CTO, Milano, Milan, Italy
Background/Purpose: BAG3 (Bcl2-associated athanogene 3) regulates cellular pathways including apoptosis and autophagy, and induces fibroblast-to-myofibroblast transformation. In systemic sclerosis (SSc), myofibroblasts drive fibrosis of skin…
Abstract Number: 1571 • ACR Convergence 2025
Spatial Transcriptomics of Perivascular Subepidermal Regions in Very Early Systemic Sclerosis Unveils Cellular and Mitochondrial Stress-Driven Innate Immune Signatures that Initiate Stromal Remodeling
Ifeoluwa Emmanuel Bamigbola¹, Jayakumar Vadakekolathu¹, Stefano Di Donato², Vishal Kakkar³, Rebecca Ross⁴, Yasser El-Sherbiny¹ and Francesco Del Galdo³, ¹¹Nottingham Trent University, Department of Biosciences, School of Science and Technology, Nottingham, United Kingdom, ²University of Leeds, Canosa Sannita, Chieti, Italy, ³University of Leeds, Leeds, United Kingdom, ⁴Medicine and Health, University of Leeds, Leeds, United Kingdom
Background/Purpose: The skin from patients with Very Early Diagnosis of Systemic Sclerosis (VEDOSS) already exhibits fibrotic alterations such as collagen deposition and perivascular infiltration (1),…
Abstract Number: 1079 • ACR Convergence 2025
Sociodemographic, Clinical, and Community-Level Deprivation Factors are Associated with Health-Related Quality of Life in Systemic Sclerosis
Sarah Smith¹, Paula Ramos², Dulaney Wilson³, Diane Kamen⁴ and Richard Silver¹, ¹Medical University of South Carolina, Charleston, SC, ²Emory University School of Medicine, Atlanta, GA, ³Medical University of South Carolina, Charleston, ⁴Medical University of South Carolina, Johns Island, SC
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease with heterogeneous manifestations and significant impairment in health-related quality of life (HRQoL). SSc outcomes are shaped…
Abstract Number: 0959 • ACR Convergence 2025
Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score
Bich Na Choi¹, Claudia Pedroza², Brian Skaug³, Maureen Mayes⁴ and Shervin Assassi⁵, ¹UTHealth Houston Institute for Clinical Research & Learning Health Care, Houston, TX, ²UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴UT Health Houston Division of Rheumatology, Houston, TX, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX
Background/Purpose: Clinically useful biomarkers for systemic sclerosis (SSc) are needed. While obtaining samples from affected organs like the skin and lungs is invasive and cannot…
Abstract Number: 0687 • ACR Convergence 2025
Distinct Cancer Risk Profiles in Patients with Systemic Sclerosis with Autoantibody Stratification
Arjun Mahajan¹, Nikki Zangenah², Maria Vazquez-Machado², Avery LaChance³ and Jeffrey Sparks⁴, ¹Harvard Medical School, Boston, ²Brigham and Women's Hospital, Harvard Medical School, Boston, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with systemic sclerosis (SSc) face increased cancer risk compared to the general population, yet current evidence on specific cancer patterns and their relationship…
Abstract Number: 0883 • ACR Convergence 2025
Predictive Significance of Serum Proteins for the Course of Systemic Sclerosis-Related Interstitial Lung Disease in the Multicenter CONQUER Cohort
Ali Ayla¹, Chenyue Huang², Claudia Pedroza³, Meng Zhang⁴, John VanBuren⁵, Flavia Castelino⁶, Lorinda Chung⁷, Luke Evnin⁸, Tracy Frech⁹, Jessica Gordon¹⁰, Faye Hant¹¹, Laura Hummers¹², Dinesh Khanna¹³, Kimberly Lakin¹⁰, Dorota Lebiedz-Odrobina⁵, Yiming Luo¹⁴, Ashima Makol¹⁵, Maureen Mayes¹⁶, Zsuzsanna McMahan¹⁷, Jerry Molitor¹⁸, Duncan Moore¹⁹, Carrie Richardson²⁰, Nora Sandorfi²¹, Ami Shah¹², Ankoor Shah²², Victoria Shanmugam²³, Brian Skaug¹, Virginia Steen²⁴, Elizabeth Volkmann²⁵, Carleigh Zahn¹³, Wenjin J Zheng², Elana Bernstein¹⁴ and Shervin Assassi²⁶, ¹UTHealth Houston Division of Rheumatology, Houston, TX, ²UTHealth Houston, Houston, ³UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ⁴UTHealth Houston Division of Rheumatology, Houston, ⁵University of Utah, Salt Lake City, UT, ⁶Massachusetts General Hospital, Boston, MA, ⁷Stanford University, Stanford, CA, ⁸Scleroderma Research Foundation, Brisbane, CA, ⁹Vanderbilt University Medical Center, Nashville, TN, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Columbia University, New York, NY, ¹⁵Mayo Clinic, Rochester, MN, ¹⁶UT Health Houston Division of Rheumatology, Houston, TX, ¹⁷UT Health Houston, Houston, TX, ¹⁸University of Minnesota, Minneapolis, MN, ¹⁹Northwestern Memorial Hospital, Chicago, IL, ²⁰Northwestern University, Chicago, IL, ²¹University of Pennsylvania, Philadelphia, PA, ²²Duke University, Durham, NC, ²³National Institutes of Health, Great Falls, VA, ²⁴Georgetown University School of Medicine, Washington, DC, ²⁵Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²⁶Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX
Background/Purpose: The course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable and difficult to predict using clinical variables alone. Therefore, there…
Abstract Number: 0006 • ACR Convergence 2025
QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
Jenny McGovern, Georgios Eleftheriadis, Thomas Grothier, Eva Bugallo Blanco, Anna Koi, Mahsa Nemani, Cameron Allum, Emily Hurley, Daniela Penston, Marc Martinez-Llordella, Luke Devey and Nathalie Belmonte, Quell Therapeutics, London, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) are immune mediated inflammatory diseases (IMID) where a complex interplay of tissue and immune cell activation drives…
Abstract Number: 2497 • ACR Convergence 2025
Unraveling the Complexity of Interferon Responses in Peripheral Blood Mononuclear Cells in Systemic Sclerosis at Single-Cell Resolution
Pietro Bearzi¹, Elena Pachera², Astrid Hofman³, Laura Much⁴, Lumeng Li¹, Kristina Bürki³, Cosimo Bruni⁵, Mike Becker⁶, Anna-Maria Hoffmann-Vold⁷, Roberto Giacomelli⁸ and Oliver Distler⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵University of Zurich, Zurich, Switzerland, ⁶Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ⁷Oslo University Hospital, Oslo, Norway, ⁸i) Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Biomedico; ii) Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome "Campus Bio-Medico", Rome, Italy, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Autoimmunity is a hallmark of SSc pathogenesis. Emerging evidence suggests that interferon (IFN) signaling plays a role in predicting SSc patients at risk of…
Abstract Number: 2485 • ACR Convergence 2025
Prevalence of progressive pulmonary fibrosis in systemic sclerosis-associated interstitial lung disease
Javier Narváez¹, Irene Carrión-Barberà², Carlos Valera Ribera³, Alfredo Guillen del Castillo⁴, Laura Tio⁵, Laura Triginer⁶, Lidia Montala-Valencia⁷, Carmen Pilar Simeon⁸, Anna Pros², JUAN JOSE ALEGRE SANCHO⁹ and Joan Miquel Nolla¹⁰, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology. Hospital del Mar, Barcelona, Spain, ³Hospital Universitario Doctor Peset, València, Spain, ⁴Departmend of Internal Medicine. Hospital Universitario Vall d´Hebron, Barcelona, Spain, ⁵Hospital del Mar Research Institute, Barcelona, Spain, ⁶Vall d´Hebron Institut de Recerca (VHIR), Barcelona, Spain, ⁷Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Department of Internal Medicine, Hospital Universitario Vall d’Hebron, Barcelona, Spain, ⁹Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁰Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain
Background/Purpose: To estimate the prevalence of the progressive pulmonary fibrosis (PPF) phenotype among patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) and identify risk factors…
Abstract Number: 1861 • ACR Convergence 2025
Accelerated and Gene-Specific Patterns of Clonal Hematopoiesis Distinguish Subtypes of Systemic Sclerosis
Brecca Miller¹, Shervin Assassi², Maureen Mayes³, alejandro Molina⁴, Kelly Ruggles⁵, David Beck⁶ and Meng Zhang⁷, ¹Center for Human Genetics and Genomics, NYU Grossman School of Medicine, Brooklyn, NY, ²Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ³UT Health Houston Division of Rheumatology, Houston, TX, ⁴Georgia Institute of Technology, Atlanta, GA, ⁵NYU Grossman School of Medicine, Brooklyn, NY, ⁶Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ⁷UTHealth Houston Division of Rheumatology, Houston
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by widespread fibrosis, vasculopathy, autoantibody presence, and high mortality in its diffuse subtype with limited effective…
Abstract Number: 1570 • ACR Convergence 2025
Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses
Francesco Bonomi¹, Ilaria Bisconti², Ilenia Mallia³, Greta Pellegrino⁴, Gabriele Ciuti⁵, Gloria Muolo², Martina Salerno², Simona Truglia², Cristiano Barbetta³, Silvia Peretti⁵, Serena Guiducci⁶, Valeria Riccieri⁷ and Silvia Bellando Randone³, ¹University Hospital Careggi, Florence, Florence, Toscana, Italy, ²Sapienza University of Rome, Rome, Rome, Italy, ³University of Florence, Florence, Italy, ⁴Rheumatology Unit, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milano, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, ⁵University Hospital Careggi, Florence, Italy, ⁶Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ⁷Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Roma, Italy
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug that interferes with dendritic cells and monocytes, acidifies endosomes, and modulates toll-like receptors, reducing autoimmune responses and cell…
Abstract Number: 1037 • ACR Convergence 2025
Risk Factor Identification and Dynamic Individualized Prediction of Muscle Involvement in Systemic Sclerosis
Zixing Liu¹, Adrianne Woods², Julie Paik², Laura Hummers², Scott Zeger¹, Ami Shah² and Ji Soo Kim³, ¹Johns Hopkins Biostatistics, Baltimore, MD, ²Johns Hopkins Rheumatology, Baltimore, MD, ³Johns Hopkins, Baltimore, MD
Background/Purpose: Myopathy in SSc significantly increases disability, reduces quality of life, and elevates mortality risk, yet remains understudied. Most identified risk factors derive from cross-sectional…
Abstract Number: 0960 • ACR Convergence 2025
Pharmaceutical Blockade of the Neonatal Fc Gamma Receptor Ameliorates Autoimmunity, Inflammation and Fibrosis in the Topoisomerase I Mouse Model of Systemic Sclerosis
Cuong Tran-Manh¹, Thuong Trinh-Minh², Christoph Liebel³, Bas van der Woning⁴, Piotr Zabrocki⁵ and Jörg Distler⁶, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Nordrhein-Westfalen, Germany, ²Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁴argenx BV, Boston, MA, ⁵argenx, Ghent, Belgium, ⁶University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: SSc is a rare, chronic, systemic autoimmune rheumatic disease characterized by progressive skin and internal organ fibrosis, severe vasculopathy and immune dysregulation with production…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].